< Back Beauty-From-Within Marketing: Best Practices and Pitfalls to Avoid Asa Waldstein Guest Article Read More Previous Next

Asa and other industry leaders interviewed in the New Hope article. < Back FDA rejects two new dietary ingredient submissions for CBD, leaving hemp industry with legislation as only route to clarity Rick Polito Interview Asa and other industry leaders interviewed in the New Hope article. Read More Previous Next

< Back Virtual Fireside Chat Friday Jan 19, 2024 Radicle Perspectives: Elevating the supplement industry Radicle Science There was no shortage of dietary supplement regulation and compliance talk in 2023. From FTC guidance and FDA’s response to NAC and NMN, to the Dietary Supplements Access Act, continued market disruption due to supply chains and inflation, not to mention authenticity issues continuing to plague major online retailers, what can we anticipate in 2024? Tune in to another insightful episode of Radicle Perspectives as we welcome our esteemed guest, Asa Waldstein, as we prognosticate about what 2024 has in store for dietary supplement regulations and compliance. Key Topics: Recap major industry news from 2023. Anticipate how these headlines from 2023 will impact regulations and compliance in 2024. Learn about other dietary supplement regulations and compliance issues beginning to percolate already. Register Previous Next

< Back Panel Discussion Wednesday Sep 21, 2022 Building Brands in Cannabis Naturally Boulder Boulder, CO CBD, THC, and Cannabis are all over the news. Consumers see the products in stores, are starting to see limited advertising, and are hearing anecdotes from their friends. Everyone is talking about it, but people have very little information about it. And, the information they do have varies by the state or community they live in. This creates an interesting business opportunity for entrepreneurs! For current brands looking to incorporate cannabinoid-based benefits of sleep, pain relief or calm there is obvious opportunity, but also, complexity and risk. For new brands launching into the space, there is a steep and unique learning curve in navigating formulation, branding, and distribution that is like no other industry. If you’ve wanted to learn more about this continually emerging, high-growth industry, Naturally Boulder has assembled a panel of experts to discuss the state of the industry, what’s hot and new, and how you can develop and build a powerhouse brand in the space. Learn More Previous Next

< Back In-Person, Panel Discussion Wednesday Jun 25, 2025 Leveraging AI in Dietary Supplement R&D: Harnessing Innovation While Navigating Key Regulatory and IP Risks  American Conference Institute New York, NY As the dietary supplements industry continues to evolve, innovation is driving new product development and improved efficiencies.  From AI-powered R&D to advancements in manufacturing and supply chain optimization, companies are embracing cutting-edge technologies to stay competitive. However, these innovations also introduce complex regulatory, intellectual property, and compliance risks that must be carefully navigated.  Join industry leaders and experts as they explore:  AI’s role in dietary supplement R&D and product development: how artificial intelligence is transforming ingredient discovery, formulation, and clinical research  Understanding the applicable guidelines for using AI to support regulatory submissions/documents (GRAS, NDI, claims registrations, etc.) focused on safety, quality and efficacy of ingredients Navigating evolving FDA oversight and safety considerations when utilizing AI in product development Understanding the IP and competitive risks: navigating issues that can arise regarding the patentability of AI-discovered ingredients and formulations Learn More and Register Previous Next

The American Herbal Products Association hosted its first botanical congress outside the confines of the SupplySide Global trade show. < Back AHPA leans on past to embrace high-tech future at botanical congress Claudia Adrien Press Mention The American Herbal Products Association hosted its first botanical congress outside the confines of the SupplySide Global trade show. Read More Previous Next

Some of our favorite resources to help educate about marketing compliance. Marketing Compliance / Marketing Compliance These are common areas of enforcement and lawsuits.Here are some resources to help understand these regulations. Substantiation Tips and CARSE Health Products Compliance Guidance TikTok Music Copyright Litigation & Best Practices Common Plaintiff Lawsuits: Best Practices Asa's weekly Warning Letter Wednesday post FTC Document: How to Make Effective Disclosures in Digital Advertising FTC Document: Social Media Disclosures FTC's Dietary Supplement Advertising Guide For Industry Made in the USA lawsuit reference (TINA) Natural Claims article Made in the USA (Great Podcast!) Made in the USA FTC Guidance AHPA Hemp CBD Supplement Congress videos! FDA Label Claim Guidance FTC Guidance: Claim Substantiation FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising AHPA Alerts: Stay up to date (AHPA members only) Other AHPA Guidance Documents Compliance essential for hemp CBD companies: Marketing FDA alerts (allergens, recalls, warning letters) Back

Asa Waldstein is our guest on KISC My Health Radio show with Peter Mingils and the King of Cranberries Stephen Lukawski. < Back KISC My Health Radio Show with Captain Cran Man Stephen Lukawski with Asa Waldstein and cohost Peter Mingils Stephen Lukawski Podcast Interview Asa Waldstein is our guest on KISC My Health Radio show with Peter Mingils and the King of Cranberries Stephen Lukawski. This week on KISC My Health Radio, Captain Cran Man Stephen Lukawski and Peter Mingils have the privilege of interviewing Asa Waldstein. Click "read more" below to learn more and listen to the interview. Read More Previous Next

Asa is interviewed by a well-known influencer on the topic. This is applicable to the dietary supplement industry as well. Read here: https://www.letstalkhemp.com/hemp-influencers/ < Back Influencers and CBD: Be Careful What You Say Cait Curley and Asa Waldstein Interview Asa is interviewed by a well-known influencer on the topic. This is applicable to the dietary supplement industry as well. Read here: https://www.letstalkhemp.com/hemp-influencers/ Read More Previous Next

Batch records should be complete < Back Improper Written Specifications Lead To Warning Letter Batch records should be complete This warning letter is interesting as it details some of FDA's thinking on test methods. Upon my initial reading of this letter, it seemed like FDA had an issue with HPTLC, but the problem was actually how the specification was written. HPTLC is mentioned in this letter. Here FDA states that HPTLC is not a parameter that can be tested to. More information is needed, such as the plant’s genus, species, and the plant part. From warning letter. “HPTLC” is not a qualitative or quantitative parameter to which a test result can be compared to verify the identity of the component.” Thanks to my friends at Alkemist Labs for talking this through with me. Your expertise is very appreciated! This is a shortened version of Warning Letter Wednesday as I’m currently attending Supplyside West. If you are here and want to discuss consulting or Apex Compliance™ Compliance, let me know. There are also other GMP violations in the letter, such as incomplete batch records. This example FDA cites the company for not having cleaning records. When I was a manufacturer, we would attach cleaning records to each batch record. As FDA notes below, this is not needed, but cross-referencing this information is required. 👉 From warning letter. “Your batch production record fails to include the date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch or a cross-reference to records, such as individual equipment logs, where this information is retained.” I recommend reading the full warning letter , as there are other labeling and testing citations that provide good learning opportunities. Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading. Previous Next Get Warning Letter Wednesday in your Inbox Sign-Up Now!

Use caution when promoting blood sugar products. Remove claims on social media. < Back “Blood sugar” enforcement risks and review Use caution when promoting blood sugar products. Remove claims on social media. #WarningLetterWednesday; Blood sugar claims enforcement remains top of mind for the FDA. Since January 2021, there have been 36 blood sugar related warning letters. 🔷Blood sugar support is not a high-risk claim, but it becomes very high-risk when correlated with a disease such as diabetes. Not surprisingly, nearly 78% of the warning letters include the words diabetes or diabetic. The remaining eight that only mentioned "blood sugar" also contain high-risk words such as cancer and depression. These claims were made on Amazon, social media, testimonials, videos, and product tags. I expect to see more warning letters calling out claims on these platforms, especially with claims made in videos and testimonials. 🔷Testimonials: Claims made in testimonials were cited nearly 30% of the time, which is a strong enforcement trend to be aware of. Here is a video about why product reviews and testimonials can be considered marketing claims. 🔷Blogs: 22% of the warning letters include claims made in blogs. The line between "educational" and "product blogs" is thin. I talk about this here . 👉Here is a learning tool titled "Protect Your Company: Learn to read warning letters ." 🔷Social Media: Claims made on social media represent nearly 64% of these letters. The FDA is paying close attention to social media posts. I expect the number of social media related warning letters to increase, especially since the FDA is going back several years on company social media posts. They look at several year old posts in the same manner as current ones. Here is a video about reasons to clean up old social media posts. 🔷Hashtags: 25% of these letters include claims made in hashtags. This is a strong enforcement trend to watch. Here is a video about this. 🔷🔷Key Takeaways🔷🔷 👉Blood sugar marketing statements should be used with caution. 👉The word diabetes should be avoided. 👉Remove claims and high-risk words on all marketing platforms . 👉Blogs, hashtags, and social media are under increased scrutiny. What enforcement trends are interesting to you? Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading. Previous Next Get Warning Letter Wednesday in your Inbox Sign-Up Now!

Congress said to legalize it, and left it to FDA to figure out details. FDA's position: pound sand. < Back FDA ups the ante in its war against CBD Todd Runestad Interview Congress said to legalize it, and left it to FDA to figure out details. FDA's position: pound sand. Read More Previous Next